Develops AI-powered robotic ultrasound image guidance for cardiac procedures
Laza Medical, Inc.
Campbell, CA (USA)New on Amplifa
About Laza Medical
Laza Medical is a private medical technology company headquartered in Campbell, California, developing an AI-powered robotic ultrasound image guidance system for structural heart interventions and electrophysiology. The platform combines real-time 3D cardiac modeling based on ultrasound data, step-by-step procedural guidance, robotic probe control, and an intuitive user interface. The goal is to simplify image acquisition and interpretation, reduce the burden on clinical teams, and improve access to image-guided cardiac procedures. Laza Medical was founded by experts from medtech robotics, imaging, and AI and is a portfolio company of the medical innovation hub Shifamed. The system is in clinical testing and is not yet approved for use in any country.
- Site
- Campbell, CA, USA
- Processes
- AI-powered 3D cardiac modeling, Robotic ultrasound probe control, Procedural guidance for structural heart interventions and electrophysiology
- Materials
- AI-powered 3D cardiac modeling, Robotic probe control, Procedural guidance
- Certificates
- System approval
- Employees
- 2-10
- Industries
- Medical Technology, Medical Robotics, Medical Imaging, Cardiology
- 01
AI-based software development (3D cardiac modeling)
- 02
Robotics and systems development
- 03
Ultrasound engineering
- 04
Regulatory quality assurance
- 05
Clinical testing
Technology and Processes
AI-powered 3D cardiac modeling
Constructs a patient-specific 3D heart model in real time using ultrasound data alone.
Robotic probe control
Aims to enable image-guided navigation of the ultrasound probe and, in the long term, robotically assisted TEE control.
Procedural guidance
Provides echo-based tracking of anatomy and devices for step-by-step procedure guidance.
Locations
Campbell
USHeadquarters, development
Industries
Additional services
Quality and Regulatory
The company maintains functions for Regulatory, Quality Assurance, and Clinical Affairs. The system is in preclinical or early clinical testing and is not yet approved for sale.
| Evidence | Campbell |
|---|---|
| System approval |
Company History
- 2023
Investment by 415 Capital
- 2024
Series A financing of USD 36 million completed (Shifamed portfolio company)
- 2025
First-in-human use of the real-time AI heart model for ultrasound-guided cardiac procedures at Oregon Health Sciences University Hospital (software-only, retrospective analysis during ongoing procedures)